Xiagem DS 1 Tablet PR is a combination oral hypoglycemic agent containing Glimepiride 1 mg and Metformin 1000 mg, indicated for the management of type 2 diabetes mellitus. Glimepiride, a sulfonylurea class drug, stimulates pancreatic beta cells to increase insulin secretion, thereby improving glycemic control. Metformin, a biguanide, primarily decreases hepatic glucose production and enhances peripheral insulin sensitivity, contributing to improved glucose uptake and utilization. The dual mechanism of action targets both insulin resistance and insulin secretion defects commonly observed in type 2 diabetes. Xiagem DS 1 Tablet PR is prescribed as part of a comprehensive diabetes management plan including diet, exercise, and weight control. It is particularly beneficial for patients inadequately controlled on monotherapy or requiring combination therapy for optimal glycemic control. The extended-release formulation allows for once-daily dosing, improving patient compliance. Common adverse effects may include gastrointestinal disturbances such as nausea, diarrhea, and abdominal discomfort, which often subside with continued use. Hypoglycemia is a potential risk due to Glimepiride and requires patient education on symptom recognition and management. Regular monitoring of blood glucose, renal function, and liver enzymes is recommended during therapy. Xiagem DS 1 Tablet PR should be used cautiously in patients with renal impairment, hepatic dysfunction, or cardiovascular disease.